AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19291787
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment groups (Interferon and Control)
Trial: 17574311
Drug: Lyophilized formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized formulation of RTS,S/AS02A
Trial: 17574311
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of RTS,S/AS02A
Trial: 15614114
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g orally)
Trial: 15614114
Drug: Dual treatment
RxNorm normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual treatment (azithromycin and benzathine penicillin)
Trial: 15614114
Drug: Initial titers
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial titers < or =1:2 (all treatments)
Trial: 12527500
Drug: IgM-enriched immunoglobulin
RxNorm normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-enriched immunoglobulin (Pentaglobin(R)) preparation (1,300 ml immunoglobulin, equivalent to 65 g protein)
Trial: 12527500
Drug: Routine antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotic prophylaxis plus placebo
Trial: 12527500
Drug: IgM-enriched immunoglobulin
RxNorm normalized name: IgM-enriched immunoglobulins
DrugBank: Pentaglobin (DB15865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM-enriched immunoglobulin (Pentaglobin(R)) preparation
Trial: 9703374
Drug: 250 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 microg potassium iodide daily for 4 months
Trial: 9703374
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no iodine treatment)
Trial: 2506603
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg adinazolam mesylate
Trial: 2506603
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg adinazolam mesylate
Trial: 2506603
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg adinazolam mesylate
Trial: 31123181
Drug: Hyperfiltration (iGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfiltration (iGFR levels ≥140 ml/min per 1.73 m2)
Trial: 31123181
Drug: Baseline GFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline GFR <140 ml/min per 1.73 m2
Trial: 25504002
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus dexmedetomidine (10 µg)
Trial: 25504002
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus clonidine (75 µg)
Trial: 25504002
Drug: Bupivacaine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine plus fentanyl (15.0 µg)
Trial: 23831069
Drug: Bupivacaine infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine infiltration (20 mL of 0.25%)
Trial: 18089864
Drug: Psychoeducation (six
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducation (six weekly 2-hour sessions)
Trial: 15323591
Drug: Gepirone ER
RxNorm normalized name: gepirone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone ER (20 mg to 80 mg daily)
Trial: 3982576
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same treatment as before)
Trial: 10702886
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate 200 mg
Trial: 8734724
Drug: Resistance load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance load of 5 cm H2O/L/sec
Trial: 6218350
Drug: Erythromycin lauryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin lauryl sulfate (A-137) alcoholic solution, applied topically 3 times daily for 8 weeks.
Trial: 6218350
Drug: Vehicle (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (control group), applied topically 3 times daily for 8 weeks.
Trial: 26403160
Drug: Vaniprevir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaniprevir (300 mg twice daily) plus peginterferon alfa-2b and ribavirin for 12 weeks then peginterferon alfa-2b and ribavirin for 12 weeks
Trial: 26403160
Drug: Vaniprevir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaniprevir (300 mg twice daily) plus peginterferon alfa-2b and ribavirin for 24 weeks
Trial: 22516981
Drug: Individualized or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized or fixed‐dose GH treatment
Trial: 12491045
Drug: Chemotherapy for
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy for chondrosarcomas
Trial: 10636472
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg flumazenil
Trial: 31073124
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 100 µg/vilanterol 25 µg (FF/VI)
Trial: 26520926
Drug: NtRTI-sparing regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NtRTI-sparing regimen (darunavir 800 mg once per day + ritonavir 100 mg once per day + raltegravir 400 mg twice per day)
Trial: 26520926
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (darunavir 800 mg once per day + ritonavir 100 mg once per day + tenofovir 245 mg once per day + emtricitabine 200 mg once per day)
Trial: 19801029
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin (50 U/kg, max 5,000 U)
Trial: 19801029
Drug: Intra-arterial heparin
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial heparin (50 U/kg, max 5,000 U)
Trial: 16891758
Drug: Daily walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily walking for 4 weeks
Trial: 7901979
Drug: Electromyostimulation during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromyostimulation during follow-up treatment
Trial: 7901979
Drug: Follow-up treatment
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up treatment
Trial: 3425350
Drug: Enprofylline (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline (mean plasma concentration 3 mg l‐1)
Trial: 3425350
Drug: Theophylline (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (mean plasma concentration 9 mg l‐1)
Trial: 30219823
Drug: Low-dose methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methotrexate (LDMTX) 5-15 mg/week
Trial: 27630212
Drug: DPP-4i therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4i therapy (including sitagliptin)
Trial: 23061387
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg intravenous every 12 hours)
Trial: 23061387
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg intravenous every 6 hours)
Trial: 23061387
Drug: Omeprazole (high-dose:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (high-dose: 80 mg bolus plus 8 mg/hr infusion for 3 days, then 40 mg intravenous every 12 hours for 7 days)
Trial: 21216122
Drug: Ten-cha (Rubus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ten-cha (Rubus suavissimus) 400mg (3 capsules/day) for 4 weeks
Trial: 21216122
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 capsules/day) for 4 weeks
Trial: 19893562
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic and analgesics
Trial: 16843192
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Simvastatin 20 mg + Fenofibrate 160 mg)
Trial: 8267390
Drug: Adjuvant perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant perioperative portal infusion with Fluorouracil and Mitomycin
Trial: 3512326
Drug: Acyclovir cream
RxNorm normalized name: Acyclovir Cream
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir cream applied 4 times per day for 16 weeks
Trial: 3512326
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied 4 times per day for 16 weeks
Trial: 28815419
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg daily for the first week, then 100 mg for the following seven weeks)
Trial: 25154706
Drug: Intramuscular typhoid
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular typhoid vaccination
Trial: 21252013
Drug: Autologous skeletal
RxNorm normalized name: Spongia officinalis skeleton extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous skeletal myoblast therapy
Trial: 17357282
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with antibiotics
Trial: 9188228
Drug: Surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical periodontal therapy
Trial: 16600924
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) 50 mug/d plus 500 mg Ca/d
Trial: 16600924
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 500 mg Ca/d
Trial: 14750575
Drug: Prednisolone treatment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone treatment starting at 40 mg per day, tapering over 4 months
Trial: 11203411
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone (250 pg/12 hours) for 3 months
Trial: 8725679
Drug: Missed dialysis
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Missed dialysis treatments
Trial: 3909958
Drug: ACV-IFN combination
RxNorm normalized name: ACV tripeptide
DrugBank: ACV tripeptide (DB02025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACV-IFN combination
Trial: 3909958
Drug: ACV-Placebo combination
RxNorm normalized name: ACV tripeptide
DrugBank: ACV tripeptide (DB02025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACV-Placebo combination
Trial: 30702372
Drug: 6 mg·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg·kg‐1 of caffeine
Trial: 30702372
Drug: 2 mg·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg·kg‐1 of caffeine
Trial: 30702372
Drug: 4 mg·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg·kg‐1 of caffeine
Trial: 17690882
Drug: RBC transfusion
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC transfusion to maintain Hb levels >or=10 g/dl (arm 1)
Trial: 17690882
Drug: RBC transfusion
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC transfusion to maintain Hb levels >or=12 g/dl (arm 2)
Trial: 10686454
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation (INR 2.0-3.0)
Trial: 10686454
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dipyridamole (400 mg daily) plus aspirin (30-325 mg daily)
Trial: 9495426
Drug: Tropisetron 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 0.5 mg
Trial: 1387073
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy alone (control group)
Trial: 19804593
Drug: 5-aminolaevulinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-aminolaevulinic acid (5-ALA) patch-PDT
Trial: 22944145
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of markers
Trial: 16424843
Drug: L-glutamate (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-glutamate (n = 10)
Trial: 10212170
Drug: L-arginine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine infusion (10% solution, 5 ml/kg for 30 minutes)
Trial: 31124147
Drug: 6 mm
RxNorm normalized name: I-Port, 6 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mm implants alone
Trial: 31124147
Drug: 8 mm
RxNorm normalized name: potassium 8 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mm implants + OSFE
Trial: 31124147
Drug: 10 mm
RxNorm normalized name: potassium 10 MMOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mm implants + OSFE
Trial: 28701288
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose fentanyl (33 μg kg−1 loading dose, 0.2 μg kg−1 minute−1)
Trial: 28701288
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose fentanyl (102 μg kg−1 loading dose, 0.8 μg kg−1 minute−1)
Trial: 26664151
Drug: L-carnitine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 600 mg oral daily
Trial: 21668522
Drug: Micafungin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (100 mg day(-1) for adults; 2 mg kg(-1) day(-1) for children)
Trial: 21668522
Drug: Micafungin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (100 or 150 mg day(-1))
Trial: 21668522
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B (L-AmB 3 mg kg(-1) day(-1))
Trial: 21668522
Drug: Caspofungin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (50 mg day(-1); 70 mg loading dose)
Trial: 21668522
Drug: All drugs
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drugs (Micafungin, L-AmB, Caspofungin)
Trial: 18295615
Drug: Twelve‐week adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve‐week adherence intervention (weekly phone calls and home visit) including counseling on establishing, monitoring, and problem‐solving in maintaining a home exercise program
Trial: 16932345
Drug: Non-infusional consolidation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-infusional consolidation chemotherapy (mini-ICE regimen)
Trial: 16932345
Drug: Intravenous consolidation
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous consolidation chemotherapy (mini-ICE regimen)
Trial: 16932345
Drug: Both non-infusional
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both non-infusional and intravenous consolidation chemotherapy
Trial: 9334893
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg daily for 20 weeks)
Trial: 9334893
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after withdrawal from fluoxetine)
Trial: 2930987
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg cyproterone acetate (CA) + Diane (2 mg CA + 50 micrograms ethinyloestradiol) for 9 months
Trial: 2930987
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg cyproterone acetate (CA) + Diane (2 mg CA + 50 micrograms ethinyloestradiol)
Trial: 2930987
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Diane (2 mg CA + 50 micrograms ethinyloestradiol)
Trial: 2930987
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose CA
Trial: 26481764
Drug: Kidney injury
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kidney injury molecule‐1 (KIM‐1) measured 24 h after operation
Trial: 24682986
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with 0.1% ropivacaine+0.1 μg/mL sufentanil (for postoperative 48 h)+injected pethidine on demand
Trial: 24682986
Drug: Oral analgesia
RxNorm normalized name: P-A-C Analgesic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesia with controlled-release oxycodone (2x15 mg for the first postoperative 24 h; 2x10 mg for the second postoperative 24 h)+paracetamol and tramadol hydrochloride tablets (8x1 tablet for the postoperative 48 h) orally+injected pethidine on demand
Trial: 12097688
Drug: Zinc-restricted diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc-restricted diet (4.6 mg/d) during the 10-week zinc-restriction (ZR) period
Trial: 12097688
Drug: Zinc supplements
RxNorm normalized name: Zinc Supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplements (9.1 mg/d) during the 5-week baseline (BL) and 5-week repletion (RP) periods
Trial: 10424318
Drug: digoxin 0.25
RxNorm normalized name: digoxin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: digoxin 0.25 mg twice daily
Trial: 7548447
Drug: Se-rich bread
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Se-rich bread with 100, 200, and 300 micrograms Se daily for 6 weeks
Trial: 7548447
Drug: 400 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 micrograms selenomethionine daily for 15 weeks
Trial: 6998594
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of the live oral typhoid vaccine Ty21a (1 x 10(9)‐8 x 10(9) live bacteria)
Trial: 20684724
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of placebo
Trial: 29143869
Drug: MDMA 75
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA 75 mg with Ketanserin 40 mg
Trial: 20639792
Drug: Preterm formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preterm formula containing 0.8 g/100 mL short‐chain galacto‐oligosaccharides/long‐chain fructo‐oligosaccharides in a 9:1 ratio
Trial: 11887119
Drug: Mailed physician
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mailed physician reminders (4 monthly reminders)
Trial: 3359804
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 110 mg retinyl palmitate (vitamin A supplementation)
Trial: 18418239
Drug: Adjunctive balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive balloon postdilation (ABP)
Trial: 18418239
Drug: No adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjunctive balloon postdilation (no ABP)
Trial: 3514363
Drug: metronidazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metronidazole (200 mg)
Trial: 3401284
Drug: Bezafibrate (BZF)
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (BZF) 400-600 mg/day for 15-30 days
Trial: 3401284
Drug: Bezafibrate (BZF)
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (BZF) 400 mg/day for 15 days
Trial: 30838669
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training based on physical activity recommendation from WHO (PAR group)
Trial: 29165355
Drug: Nitrate-rich beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich beetroot juice (HI-NI; 140 mL containing 12.9 mmol nitrate)
Trial: 25862491
Drug: Pelvic floor
RxNorm normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic floor muscle training (PFMT) program, 12 group sessions, twice a week, 30 min each.
Trial: 24304733
Drug: Oral methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methionine load (OML) test
Trial: 16983180
Drug: Methimazole treatment
RxNorm normalized name: Methimazole
DrugBank: Methimazole (DB00763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methimazole treatment for 2 years
Trial: 27288475
Drug: Vilaprisan (VPR)
RxNorm normalized name: Vpriv
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (VPR) 0.1 mg
Trial: 27288475
Drug: Vilaprisan (VPR)
RxNorm normalized name: Vpriv
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (VPR) 0.5 mg
Trial: 27288475
Drug: Vilaprisan (VPR)
RxNorm normalized name: Vpriv
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (VPR) 1 mg
Trial: 27288475
Drug: Vilaprisan (VPR)
RxNorm normalized name: Vpriv
DrugBank: Vilaprisan (DB11971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (VPR) 2 mg